PF-00610355

Research use only, not for human use.

PF-00610355 (PF 610355) is a potent, selective, and long-acting β2-adrenoreceptor agonist with EC50 of 0.26 nM.

PF-00610355 (PF 610355) is a potent, selective, and long-acting β2-adrenoreceptor agonist with EC50 of 0.26 nM; displays 220-fold selectivity over β1; exhibits potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease.Asthma Phase 2 Discontinued.

——

PF-610355 is a long-acting (once daily) inhaled β2-adrenoreceptor agonist. PF-610355 has low oral bioavailability due to poor absorption through the gut lumen and high first pass metabolism and warranted further progression. PF-610355 has a short half-life (Clint = 33 (μL/min)/mg) that suggested an unbound intrinsic clearance of >10000 (mL/min)/kg. PF-610355 exhibits an ideal pharmacokinetic profile for an inhaled agent.

PF-610355

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

Inflammation/Immunology

Asthma

862541-45-5

617.76

C34H39N3O6S

>98% (HPLC)

——

O=C(NCC1=CC(C2=CC=C(O)C=C2)=CC=C1)CC3=CC=CC(CC(C)(NC[C@H](O)C4=CC=C(O)C(NS(=O)(C)=O)=C4)C)=C3

N-((4'-hydroxy(1,1'-biphenyl)-3-yl)methyl)-3-(2-(((2R)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)-benzeneacetamide

(-20℃)

With Ice Pack

≥ 2 years